SCHEMBL2394511

SCHEMBL2394511

CC(C)(C)OC(=O)CCCC(=O)OC(=O)CCCC(=O)OC(C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.44
ALDH1A1 P00352 1/20 0.44
EPHX2 P34913 1/20 0.40
HDAC1 Q13547 2/20 0.36
HDAC2 Q92769 2/20 0.36
HDAC6 Q9UBN7 2/20 0.36
HDAC8 Q9BY41 2/20 0.36
HDAC3 O15379 1/20 0.36
TDP1 Q9NUW8 1/20 0.34
STING1 Q86WV6 1/20 0.34
CA2 P00918 2/20 0.33
DGAT1 O75907 1/20 0.33
CYP2D6 P10635 1/20 0.33
CA1 P00915 1/20 0.33
CA7 P43166 1/20 0.33
MEN1 O00255 1/20 0.32
GAA P10253 1/20 0.32
KMT2A Q03164 1/20 0.32
CA12 O43570 1/20 0.32
CA14 Q9ULX7 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1639757 0.93 TSHR (0.50) TSHREPHX2HDAC1HDAC2HDAC6
SCHEMBL2394516 0.92 ALDH1A1 (0.48) TSHRALDH1A1EPHX2CA1DGKA
Hydrochloric Acid SCHEMBL7239543 0.90 TSHR (0.48) TSHREPHX2HDAC1HDAC2HDAC6
SCHEMBL134923 0.87 EPHX2 (0.46) TSHRALDH1A1EPHX2HDAC1HDAC2
SCHEMBL28344542 0.86 TSHR (0.46) TSHRALDH1A1EPHX2TDP1MEN1
SCHEMBL28601206 0.86 TSHR (0.46) TSHRALDH1A1EPHX2TDP1MEN1
SCHEMBL3914424 0.85 EPHX2 (0.49) TSHRALDH1A1EPHX2HDAC1HDAC2
SCHEMBL20450540 0.85 EPHX2 (0.49) TSHRALDH1A1EPHX2HDAC1HDAC2
SCHEMBL14482131 0.85 EPHX2 (0.49) TSHRALDH1A1EPHX2HDAC1HDAC2
SCHEMBL2380206 0.85 EPHX2 (0.49) TSHRALDH1A1EPHX2HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9245290-B2 Caspase inhibitors and uses thereof BUCK INSTITUTE FOR RESEARCH ON AGING (US) 2016-01-26 US disclosed
US-20140011847-A1 CASPASE INHIBITORS AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-01-09 US disclosed
US-8518942-B2 Caspase inhibitors and uses thereof BUCK INSTITUTE FOR RESEARCH ON AGING (US) 2013-08-27 US disclosed
US-20110230527-A1 CASPASE INHIBITORS AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2011-09-22 US disclosed
WO-2010017408-A1 CASPASE INHIBITORS AND USES THEREOF THE BUCK INSTITUTE FOR AGE RESEARCH (US) 2010-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230527-A1 CASPASE INHIBITORS AND USES THEREOF CASP6, CASP3, CASP2 TSHR 4710/4885ALDH1A1 4178/4885EPHX2 2543/4885
US-20140011847-A1 CASPASE INHIBITORS AND USES THEREOF CASP6, CASP3, CASP2 TSHR 4710/4885ALDH1A1 4178/4885EPHX2 2543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.